Stoke Therapeutics, Inc. Operating Expenses
Stoke Therapeutics, Inc. (STOK) reported Operating Expenses of $74.75 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-03
- Stoke Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $74.75M, a 81.81% increase year-over-year.
- Stoke Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $59.65M, a 26.03% increase year-over-year.
- Stoke Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $62.84M, a 73.27% increase year-over-year.
- Stoke Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $53.72M, a 53.95% increase year-over-year.
- Stoke Therapeutics, Inc. operating expenses for fiscal 2025 was $205.01M, a 48.64% increase from fiscal 2024.
- Stoke Therapeutics, Inc. operating expenses for fiscal 2024 was $137.93M, a 11.63% increase from fiscal 2023.
- Stoke Therapeutics, Inc. operating expenses for fiscal 2023 was $123.55M, a 5.82% increase from fiscal 2022.
- Stoke Therapeutics, Inc. operating expenses for fiscal 2022 was $116.76M, a 35.67% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $74.75M 10-Q · filed 2026-08-03 | $134.40M 10-Q · filed 2026-08-03 | $197.24M derived: sum of 3 quarters · filed 2026-08-03 | $250.97M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | $59.65M 10-Q · filed 2026-05-07 | $122.49M derived: sum of 2 quarters · filed 2026-05-07 | $176.21M derived: sum of 3 quarters · filed 2026-05-07 | $217.33M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | $62.84M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $116.56M derived: sum of 2 quarters · filed 2026-03-16 | $157.68M derived: sum of 3 quarters · filed 2026-08-03 | $205.01M 10-K · filed 2026-03-16 |
| 2025-09-30 | $53.72M 10-Q · filed 2025-11-04 | $94.84M derived: sum of 2 quarters · filed 2026-08-03 | $142.17M 10-Q · filed 2025-11-04 | $178.44M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $41.12M 10-Q · filed 2026-08-03 | $88.45M 10-Q · filed 2026-08-03 | $124.71M derived: sum of 3 quarters · filed 2026-08-03 | $159.61M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $47.33M 10-Q · filed 2026-05-07 | $83.60M derived: sum of 2 quarters · filed 2026-05-07 | $118.49M derived: sum of 3 quarters · filed 2026-05-07 | $152.67M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $36.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $71.16M derived: sum of 2 quarters · filed 2026-03-16 | $105.34M derived: sum of 3 quarters · filed 2026-03-16 | $137.93M 10-K · filed 2026-03-16 |
| 2024-09-30 | $34.90M 10-Q · filed 2025-11-04 | $69.07M derived: sum of 2 quarters · filed 2025-11-04 | $101.66M 10-Q · filed 2025-11-04 | $134.05M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $34.17M 10-Q · filed 2025-08-12 | $66.76M 10-Q · filed 2025-08-12 | $99.15M derived: sum of 3 quarters · filed 2025-08-12 | $129.69M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $32.59M 10-Q · filed 2025-05-13 | $64.98M derived: sum of 2 quarters · filed 2025-05-13 | $95.52M derived: sum of 3 quarters · filed 2025-05-13 | $126.30M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $32.39M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $62.93M derived: sum of 2 quarters · filed 2025-03-18 | $93.71M derived: sum of 3 quarters · filed 2025-03-18 | $123.55M 10-K · filed 2025-03-18 |
| 2023-09-30 | $30.54M 10-Q · filed 2024-11-05 | $61.32M derived: sum of 2 quarters · filed 2024-11-05 | $91.17M 10-Q · filed 2024-11-05 | $121.61M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $30.78M 10-Q · filed 2024-08-07 | $60.62M 10-Q · filed 2024-08-07 | $91.07M derived: sum of 3 quarters · filed 2024-08-07 | $121.12M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $29.84M 10-Q · filed 2024-05-06 | $60.29M derived: sum of 2 quarters · filed 2024-05-06 | $90.34M derived: sum of 3 quarters · filed 2024-05-06 | $118.81M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $30.44M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $60.50M derived: sum of 2 quarters · filed 2024-03-25 | $88.97M derived: sum of 3 quarters · filed 2024-03-25 | $116.76M 10-K · filed 2024-03-25 |
| 2022-09-30 | $30.05M 10-Q · filed 2023-11-07 | $58.52M derived: sum of 2 quarters · filed 2023-11-07 | $86.32M 10-Q · filed 2023-11-07 | $110.84M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $28.47M 10-Q · filed 2023-08-07 | $56.26M 10-Q · filed 2023-08-07 | $80.79M derived: sum of 3 quarters · filed 2023-08-07 | $103.47M derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $27.80M 10-Q · filed 2023-05-04 | $52.32M derived: sum of 2 quarters · filed 2023-05-04 | $75.00M derived: sum of 3 quarters · filed 2023-05-04 | $97.03M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $24.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $47.21M derived: sum of 2 quarters · filed 2023-03-06 | $69.24M derived: sum of 3 quarters · filed 2023-03-06 | $86.06M 10-K · filed 2023-03-06 |
| 2021-09-30 | $22.68M 10-Q · filed 2022-11-14 | $44.71M derived: sum of 2 quarters · filed 2022-11-14 | $61.54M 10-Q · filed 2022-11-14 | $76.13M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $22.03M 10-Q · filed 2022-08-08 | $38.86M 10-Q · filed 2022-08-08 | $53.44M derived: sum of 3 quarters · filed 2022-08-08 | $67.15M derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $16.83M 10-Q · filed 2022-05-10 | $31.41M derived: sum of 2 quarters · filed 2022-05-10 | $45.12M derived: sum of 3 quarters · filed 2022-05-10 | $58.14M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $14.59M 10-K · filed 2021-03-09 | $28.30M derived: sum of 2 quarters · filed 2021-11-08 | $41.31M derived: sum of 3 quarters · filed 2021-11-08 | $53.04M 10-K · filed 2022-03-10 |
| 2020-09-30 | $13.71M 10-Q · filed 2021-11-08 | $26.72M derived: sum of 2 quarters · filed 2021-11-08 | $38.46M 10-Q · filed 2021-11-08 | $49.53M derived: sum of 4 quarters · filed 2021-11-08 |
| 2020-06-30 | $13.01M 10-Q · filed 2021-08-10 | $24.75M 10-Q · filed 2021-08-10 | $35.82M derived: sum of 3 quarters · filed 2021-08-10 | $45.66M derived: sum of 4 quarters · filed 2021-08-10 |
| 2020-03-31 | $11.73M 10-Q · filed 2021-05-10 | $22.80M derived: sum of 2 quarters · filed 2021-05-10 | $32.65M derived: sum of 3 quarters · filed 2021-05-10 | $41.09M derived: sum of 4 quarters · filed 2021-05-10 |
| 2019-12-31 | $11.07M 10-K · filed 2021-03-09 | $20.91M derived: sum of 2 quarters · filed 2021-03-09 | $29.36M derived: sum of 3 quarters · filed 2021-03-09 | $35.68M 10-K · filed 2021-03-09 |
| 2019-09-30 | $9.84M 10-K · filed 2021-03-09 | $18.29M derived: sum of 2 quarters · filed 2021-03-09 | $24.61M 10-Q · filed 2020-11-12 | $29.15M derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-06-30 | $8.45M 10-K · filed 2021-03-09 | $14.77M 10-Q · filed 2020-08-10 | $19.31M derived: sum of 3 quarters · filed 2021-03-09 | $22.63M derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-03-31 | $6.32M 10-K · filed 2021-03-09 | $10.86M derived: sum of 2 quarters · filed 2021-03-09 | $14.18M derived: sum of 3 quarters · filed 2021-03-09 | $17.19M derived: sum of 4 quarters · filed 2021-03-09 |
| 2018-12-31 | $4.54M 10-K · filed 2020-03-23 | $7.86M derived: sum of 2 quarters · filed 2020-03-23 | $10.87M derived: sum of 3 quarters · filed 2020-03-23 | $12.78M 10-K · filed 2020-03-23 |
| 2018-09-30 | $3.32M 10-K · filed 2020-03-23 | $6.33M derived: sum of 2 quarters · filed 2020-03-23 | $8.24M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $3.01M 10-K · filed 2020-03-23 | $4.92M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $1.91M 10-K · filed 2020-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |